Skip to main content

Table 1 Patient characteristics at initial diagnosis of breast cancer

From: Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

   Dose (Gy)  
  All patients <66 ≥66  
  Median Range Median Range Median Range  
Age at initial diagnosis (years)   46 25–77 47 26–77 44 25–77  
Age at LRR (years)   48 25–78 50 26–78 46.5 25–77  
F/U from initial diagnosis (mos)   145 6–390 140 20–382 148 6–390  
F/U from XRT   94 1–218 108 1–218 92 4–164  
Stage   n % n % n % p-value
  T1 55 34.6% 26 40.0% 29 30.9% NS
  T2 76 47.8% 31 47.7% 45 47.9%  
  T3 14 8.8% 3 4.6% 11 11.7%  
  T4 7 4.4% 2 3.1% 5 5.3%  
  TX 7 4.4% 3 4.6% 4 4.3%  
  N0 81 50.9% 34 52.3% 47 50.0% NS
  N1 52 32.7% 23 35.4% 29 30.9%  
  N2 14 8.8% 6 9.2% 8 8.5%  
  N3 8 5.0% 1 1.5% 7 7.4%  
  NX 4 2.5% 1 1.5% 3 3.2%  
Primary histopathology         
  IDC 141 88.7% 56 86.2% 85 90.4% NS
  ILC 18 11.3% 9 13.8% 9 9.6%  
Tumor Grade         
  Well Diff 10 6.3% 2 3.1% 8 8.5% NS
  Mod Diff 43 27.0% 17 26.2% 26 27.7%  
  Poor Diff 86 54.1% 37 56.9% 49 52.1%  
  Unk 20 12.6% 9 13.8% 11 11.7%  
Markers         
  ER        
  Negative 70 44.0% 34 52.3% 36 38.3% 0.008
  Positive 69 43.4% 19 29.2% 50 53.2%  
  Not done/Unknown 20 12.6% 12 18.5% 8 8.5%  
  PR        
  Negative 69 43.4% 32 49.2% 37 39.4% NS
  Positive 65 40.9% 20 30.8% 45 47.9%  
  Not done/Unknown 25 15.7% 13 20.0% 12 12.8%  
  Her2        
  Negative 30 18.9% 10 15.4% 20 21.3% NS
  Positive 15 9.4% 5 7.7% 10 10.6%  
  Unknown/not done 114 71.7% 50 76.9% 64 68.1%  
Initial systemic therapy         
  Hormonal therapy only 16 10.1% 7 10.8% 9 9.6% 0.05
  Chemotherapy only 66 41.5% 21 32.3% 45 47.9%  
  Chemotherapy and hormonal therapy 32 20.1% 11 16.9% 21 22.3%  
  None 45 28.3% 26 40.0% 19 20.2%  
Initial surgery         
  MRM 141 88.7% 59 90.8% 82 87.2% NS
  Other 18 11.3% 6 9.2% 12 12.8%  
Menopausal status         
  Pre 67 42.1% 28 43.1% 39 41.5% NS
  Peri 18 11.3% 5 7.7% 13 13.8%  
  Post 63 39.6% 27 41.5% 36 38.3%  
  Unknown 11 6.9% 5 7.7% 6 6.4%  
Race         
  Asian 11 6.9% 6 9.2% 5 5.3% NS
  Black 27 17.0% 7 10.8% 20 21.3%  
  Hispanic 19 11.9% 11 16.9% 8 8.5%  
  Other 2 1.3% 1 1.5% 1 1.1%  
  White 100 62.9% 40 61.5% 60 63.8%  
  1. Comparison between escalated (≥66) and standard dose (<66) groups at time of initial treatment. ER positivity was significantly less in the standard dose group (p = 0.008). No other significant differences in patient characteristics at diagnosis between groups were seen.